Abstract
In this real-world study, for patients with acute schizophrenia, aripiprazole was effective in lowering the proportion of patients with abnormal prolactin levels, while it had no significant effect on patients with normal baseline prolactin. After adjusting for factors such as sex, age, prior antipsychotic drugs use history and disease severity, effectiveness and safety of aripiprazole in patients with normal baseline prolactin was significantly better than that in patients with elevated baseline prolactin.
Introduction
Most antipsychotic medications work by blocking dopamine D2 receptors. However, because dopamine normally inhibits prolactin secretion in the pituitary gland, blocking these receptors often leads to hyperprolactinemia (HPRL). This side effect can cause distressing issues like sexual dysfunction, bone density loss, and menstrual irregularities, which frequently lead patients to stop taking their medication.
Aripiprazole is unique because it is a D2 receptor partial agonist—it acts as a stabilizer rather than a total blocker. While clinical trials have shown it can lower prolactin, this study addresses a gap in "real-world" knowledge: Does a patient's starting prolactin level change how well the drug works for their psychiatric symptoms? In a clinical setting where patients have diverse treatment histories, understanding this relationship is crucial for personalized medicine.
Methods
Researchers conducted a post-hoc analysis of data from a large, multicenter real-world study involving 14 institutions across China. The analysis included 537 patients who had documented baseline prolactin levels.
Patients were divided into two groups based on baseline serum prolactin (PRL):
- Elevated-PRL group: ≥ 530 mIU/L (n=64)
- Normal-PRL group: < 530 mIU/L (n=473)
Patients received 10–30 mg/day of orally disintegrating aripiprazole tablets over 8 weeks. Effectiveness was measured using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) scores, and Medication Satisfaction Questionnaire (MSQ). Safety was monitored via the Udvalg for Kliniske Undersogelser (UKU) Side Effects Rating Scale.
Key Results
Prolactin Modulation
Aripiprazole demonstrated a modulating "thermostat" effect. In the elevated group, the proportion of patients with abnormal prolactin plummeted from 100% to 25% by week 8. Conversely, it had no significant effect on the normal group, suggesting it doesn't push prolactin levels below healthy thresholds.
Clinical Efficacy and Symptom Reduction
Even after adjusting for sex, age, and disease severity, the normal-PRL group showed significantly better symptom reduction across multiple clinical scales.
The normal-PRL group achieved a significantly higher reduction in PANSS total scores compared to the elevated group by the end of the study (-52.90 vs. -45.95, P = 0.0014).
By week 8, the clinical response rate was 96.6% in the normal group versus 87.8% in the elevated group.
Safety Profile
Adverse events (AEs) were more common in the elevated-PRL group (87.2%) than in the normal-PRL group (71.0%). Common AEs included akathisia (restlessness) and tremors. Baseline prolactin levels did not significantly influence aripiprazole’s effect on metabolic markers like BMI, blood glucose, or lipids, confirming the drug's relatively favorable metabolic profile.
Discussion and Conclusion
The elevated-PRL group tended to have a longer duration of illness and a higher proportion of women, suggesting that high baseline prolactin might be a marker for patients with more extensive prior exposure to other D2-blocking antipsychotics. This implies that baseline prolactin levels might be inversely correlated with the brain's "readiness" to respond to a partial agonist like aripiprazole.
These findings suggest that baseline prolactin might serve as a valuable prognostic biomarker for treatment response in schizophrenia. Patients with normal baseline prolactin levels appear to experience superior clinical improvement and better tolerability. Future prospective, randomized controlled trials are needed to confirm if baseline prolactin can be used as a definitive predictor of treatment success, potentially allowing clinicians to choose aripiprazole earlier for patients with specific biological profiles.
Summary updated